SynOx Phase 3 Study Shows TGCT Treatment Benefit
DUBLIN, IRELAND, April 13, 2026 SynOx Therapeutics has announced positive topline results from its pivotal Phase 3 TANGENT study,...
Monoclonal Antibody
Advertisement
Regeneron Dupixent EU Approval Expands Pediatric CSU Care
TARRYTOWN, N.Y. and PARIS, April 13, 2026 Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved...
Singlomics Doses First Patient in DXP-106 Trial
BEIJING, China, April 7, 2026 Singlomics Biopharmaceuticals, a clinical-stage biotechnology company focused on antibody therapeutics, announced that the first...
Tiziana Life Sciences Nasal Therapy Boosts Brain Health
Boston, MA, USA – April 1, 2026 In a promising development for age-related cognitive decline and neurodegenerative disorders, Tiziana...
Celldex Barzolvolimab Shows Strong Phase 2 Urticaria Data
Hampton, N.J., USA | March 27, 2026 Celldex Therapeutics reported compelling results from Phase 2 clinical trials of barzolvolimab,...
Advertisements
Sanofi Sarclisa SC Wins CHMP Nod for Myeloma Care
Paris, France | March 27, 2026 CHMP Recommends Innovative Subcutaneous Formulation Sanofi has achieved a major regulatory milestone as...
Harbour BioMed Reports Phase I Success for HBM9378 Antibody
Cambridge, Massachusetts, USA / Rotterdam, Netherlands / Shanghai, China | March 22, 2026 Harbour BioMed has announced the online...
Eisai and Biogen Report Strong LEQEMBI Long-Term Adherence Data
Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...
AL-S Pharma AP-101 Shows Survival Benefit in ALS Trial
ZURICH, Switzerland, March 19, 2026 AL-S Pharma AG announced new Phase 2 clinical data for its lead investigational therapy...
TREMFYA Sustains UC Remission Through 3 Years
STOCKHOLM, Sweden, Feb. 21, 2026 — Johnson & Johnson announced new long-term findings from the QUASAR long-term extension study...
Advertisement
